Rapid Readouts News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Rapid readouts. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Rapid Readouts Today - Breaking & Trending Today

Overall Survival in Patients With Primary Advanced or Recurrent Endometrial Cancer Treated With Dostarlimab Plus Chemotherapy in Part 1 of the ENGOT-EN6-NSGO/GOG-3031/RUBY Trial

Matthew Powell, MD, presents findings from a second interim analysis of part 1 from the ENGOT-EN6-NSGO/GOG-3031/RUBY trial investigating the combination of dostarlimab-gxly plus carboplatin/paclitaxel compared with placebo/chemotherapy in patients with primary advanced or recurrent endometrial cancer. ....

Matthew Powell , Overall Survival , Patients With Primary Advanced , Endometrial Cancer , Rapid Readouts ,

Cabozantinib plus Atezolizumab in Locally Advanced/Metastatic Adrenocortical Carcinoma: Results From a Multi-Cohort Basket Phase II Trial (CABATEN/GETNE-T1914)

Enrique Grande, MD, PhD, Msc, presents the results of a multi-cohort basket phase II trial, CABATEN/GETNE-T1914, evaluating cabozantinib plus atezolizumab in patients with locally advanced/metastatic adrenocortical carcinoma. ....

Enrique Grande , Metastatic Adrenocortical Carcinoma , Results From , Multi Cohort Basket Phase , Adrenocortical Carcinoma , Rapid Readouts ,

Treatment Strategies in Triple Class Refractory MM Patients

An expert explores factors influencing the selection of treatment regimens in relapsed, triple class refractory multiple myeloma (MM) patients, with a focus on prophylactic measures for managing adverse events associated with novel agents like Selinexor, bispecific, and CAR-T therapies. ....

Treatment Strategies , Triple Class Refractory , Multiple Myeloma , Xpo1 Inhibitors , Rapid Readouts , Evolving Role Of Xpo1 Inhibitors In Multiple Myeloma ,

Safety and Clinical Experience of XPO1 Inhibitors in R/R MM Patients

Dr. Usmani, MD, MBA, FACP provides insights into Selinexor's safety profile in Relapsed/Refractory Multiple Myeloma (R/R MM), comparing it with other treatments and delve into the ongoing challenges and unmet needs in R/R MM patient care. ....

Clinical Experience , Refractory Multiple Myeloma , Multiple Myeloma , Xpo1 Inhibitors , Rapid Readouts , Evolving Role Of Xpo1 Inhibitors In Multiple Myeloma ,

COMING SOON: Amivantamab Plus Chemotherapy (With or Without Lazertinib) vs Chemotherapy in EGFR-mutated, Advanced NSCLC After Progression on Osimertinib

Martin Dietrich, MD, PhD, provides a look at an upcoming program exploring key data from the phase 3 MARIPOSA-2 study in patients with EGFR-mutated advanced NSCLC. ....

Without Lazertinib , Rapid Readouts , Lung Cancer , Non Small Cell Lung Cancer , Egfr Mutant , Mariposa 2 ,